We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study
Read MoreHide Full Article
Pfizer (PFE - Free Report) announced positive overall survival data from a phase III study of Adcetris regimen in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) irrespective of CD30 expression.
The ECHELON-3 study, evaluating Adcetris in combination with lenalidomide and rituximab, demonstrated a notable improvement in the primary endpoint of overall survival compared to the standard lenalidomide and rituximab plus placebo regimen. Moreover, secondary endpoints such as progression-free survival and overall response rate also exhibited promising results, irrespective of CD30 expression.
Pfizer plans to engage with the FDA for regulatory submission based on the ECHELON-3 data.
Pfizer’s stock has declined 29.7% in the past year against an increase of 33.2% for the industry.
Image Source: Zacks Investment Research
Adcetris is presently approved for seven indications for different types of lymphoma, including classical Hodkin lymphoma (cHL), systemic anaplastic large cell lymphoma and primary cutaneous anaplastic large cell lymphoma.
DLBCL, being the most common form of lymphoma, presents significant challenges due to its rapid growth and resistance to conventional therapies. A staggering 40% of patients either do not respond to initial treatment or experience relapse after the first line of therapy. If approved by the FDA, DLBCL will be the eighth approved indication for Adcetris.
Adcetris was added to Pfizer’s product portfolio with the December 2023 acquisition of Seagen. The acquisition of Seagen has strengthened Pfizer’s portfolio of cancer drugs by adding four antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak. ADCs are being considered a disruptive innovation in the pharmaceutical industry as they will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
In the past 60 days, 2024 estimates for Vanda Pharmaceuticals have narrowed from a loss of 46 cents to earnings of 1 cent. For 2025, loss estimates have narrowed from 94 cents to 48 cents per share in the past 60 days. In the past year, shares of VNDA have declined 37.5%.
Vanda Pharmaceuticals delivered a three-quarter average earnings surprise of 92.88%.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents, while that for 2025 has increased from 32 cents to 50 cents. In the past year, shares of ADMA Biologics have risen 95.6%.
Earnings of ADMA Biologics beat estimates in three of the last four quarters while meeting the same once. ADMA delivered a four-quarter average earnings surprise of 85.0%.
In the past 60 days, estimates for GSK’s 2024 earnings per share have improved from $3.87 to $4.03, while that for 2025 has increased from $4.20 per share to $4.39. In the past year, shares of GSK have risen 29.1%.
Earnings of GSK beat estimates in three of the last four quarters while missing the same once. GSK delivered a four-quarter average earnings surprise of 7.59%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study
Pfizer (PFE - Free Report) announced positive overall survival data from a phase III study of Adcetris regimen in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) irrespective of CD30 expression.
The ECHELON-3 study, evaluating Adcetris in combination with lenalidomide and rituximab, demonstrated a notable improvement in the primary endpoint of overall survival compared to the standard lenalidomide and rituximab plus placebo regimen. Moreover, secondary endpoints such as progression-free survival and overall response rate also exhibited promising results, irrespective of CD30 expression.
Pfizer plans to engage with the FDA for regulatory submission based on the ECHELON-3 data.
Pfizer’s stock has declined 29.7% in the past year against an increase of 33.2% for the industry.
Image Source: Zacks Investment Research
Adcetris is presently approved for seven indications for different types of lymphoma, including classical Hodkin lymphoma (cHL), systemic anaplastic large cell lymphoma and primary cutaneous anaplastic large cell lymphoma.
DLBCL, being the most common form of lymphoma, presents significant challenges due to its rapid growth and resistance to conventional therapies. A staggering 40% of patients either do not respond to initial treatment or experience relapse after the first line of therapy. If approved by the FDA, DLBCL will be the eighth approved indication for Adcetris.
Adcetris was added to Pfizer’s product portfolio with the December 2023 acquisition of Seagen. The acquisition of Seagen has strengthened Pfizer’s portfolio of cancer drugs by adding four antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak. ADCs are being considered a disruptive innovation in the pharmaceutical industry as they will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Zacks Rank and Stocks to Consider
Pfizer currently has a Zacks Rank #3 (Hold).
Pfizer Inc. Price and Consensus
Pfizer Inc. price-consensus-chart | Pfizer Inc. Quote
Some better-ranked stocks in the healthcare sector are Vanda Pharmaceuticals (VNDA - Free Report) , ADMA Biologics (ADMA - Free Report) and GSK, plc (GSK - Free Report) . While Vanda Pharmaceuticals and ADMA Biologics have a Zacks Rank #1 (Strong Buy) each, GSK has a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, 2024 estimates for Vanda Pharmaceuticals have narrowed from a loss of 46 cents to earnings of 1 cent. For 2025, loss estimates have narrowed from 94 cents to 48 cents per share in the past 60 days. In the past year, shares of VNDA have declined 37.5%.
Vanda Pharmaceuticals delivered a three-quarter average earnings surprise of 92.88%.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents, while that for 2025 has increased from 32 cents to 50 cents. In the past year, shares of ADMA Biologics have risen 95.6%.
Earnings of ADMA Biologics beat estimates in three of the last four quarters while meeting the same once. ADMA delivered a four-quarter average earnings surprise of 85.0%.
In the past 60 days, estimates for GSK’s 2024 earnings per share have improved from $3.87 to $4.03, while that for 2025 has increased from $4.20 per share to $4.39. In the past year, shares of GSK have risen 29.1%.
Earnings of GSK beat estimates in three of the last four quarters while missing the same once. GSK delivered a four-quarter average earnings surprise of 7.59%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.